The Efficacy of Glucagon Like Peptide (GLP) - 1(7-36) Amide for Glycemic Control in Critically Ill Patients

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Critically Ill, Hypoglycemia

In brief

The goal of this present proposal is to examine the efficacy of GLP-1 administered to control blood glucose in critically ill patients.

Key facts

Study ID

NCT00798590

Run by

Johns Hopkins University

People needed

19

Starts

2008-12-01

Expected to finish

2011-06-01

Last updated by the study team

2017-07-02

Who can join

Age: 21 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men and women age > 21 to 75 years of age.
• All subjects who meet ICU specific criteria for inclusion in their glucose protocol and placed on insulin infusion protocol as standard of care.
• Able to obtain patient or proxy consent.

You may not qualify if…

• Current diagnosis of malignancy.
• Type 1 diabetes.
• Inability to obtain informed consent.
• On any Phase 1 trial.

Where it is running

• Johns Hopkins Bayview Medical Center — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.